-derived growth factor BB and its receptor (PDGFR␤) play a pivotal role in the development of renal glomerular mesangial cells. Their roles in increased mesangial cell proliferation during mesangioproliferative glomerulonephritis have long been noted, but the operating logic of signaling mechanisms regulating these changes remains poorly understood. We examined the role of a recently identified MAPK, Erk5, in this process. PDGF increased the activating phosphorylation of Erk5 and tyrosine phosphorylation of proteins in a time-dependent manner. A pharmacologic inhibitor of Erk5, XMD8-92, abrogated PDGF-induced DNA synthesis and mesangial cell proliferation. Similarly, expression of dominant negative Erk5 or siRNAs against Erk5 blocked PDGF-stimulated DNA synthesis and proliferation. Inhibition of Erk5 attenuated expression of cyclin D1 mRNA and protein, resulting in suppression of CDK4-mediated phosphorylation of the tumor suppressor protein pRb. Expression of cyclin D1 or CDK4 prevented the dominant negative Erk5-or siErk5-mediated inhibition of DNA synthesis and mesangial cell proliferation induced by PDGF. We have previously shown that phosphatidylinositol 3-kinase (PI3-kinase) contributes to PDGF-induced proliferation of mesangial cells. Inhibition of PI3-kinase blocked PDGF-induced phosphorylation of Erk5. Since PI3-kinase acts through Akt, we determined the role of Erk5 on Akt phosphorylation. XMD8-92, dominant negative Erk5, and siErk5 inhibited phosphorylation of Akt by PDGF. Interestingly, we found inhibition of PDGF-induced Erk5 phosphorylation by a pharmacological inhibitor of Akt kinase and kinase dead Akt in mesangial cells. Thus our data unfold the presence of a positive feedback microcircuit between Erk5 and Akt downstream of PI3-kinase nodal point for PDGF-induced mesangial cell proliferation.
modimers (19) . All these isoforms bind to two PDGF receptors (PDGFR␣ and PDGFR␤) with distinct affinity and specificity. The PDGF BB homodimer or AB heterodimer binds to both receptors. However, PDGF-C binds only to the PDGFR␣, while PDGF-D predominantly interacts with homodimeric PDGFR␤␤ and by low affinity with PDGFR␣␤ (21) .
Mesangial cells are considered vascular pericytes that constitute one-third of the cell type of glomeruli, the filtering units of the kidney. They respond to injury and contribute to the hypercellularity observed in number of glomerular diseases (1) . IgA nephropathy, membranoproliferative glomerulonephritis, and lupus nephritis are characterized by proliferation of mesangial cells (25) . Although many other growth factors stimulate proliferation of mesangial cells, PDGF, especially the BB isoform, is the most potent mitogen for these cells (1, 25) . In fact, most cytokine-induced proliferation of mesangial cells is caused by autocrine stimulation of PDGF BB. PDGFR␤ is the predominant isoform expressed in renal mesangial cells while PDGFR␣ is expressed at lower abundance (9, 40) . PDGFR␤ knockout mice display defect in glomerular mesangial cell development. A similar phenotype was observed with PDGF-B chain deletion in mice (37) .
PDGFRs are composed of a large extracellular segment containing IgG-like domains followed by juxtamembrane domain and a split COOH-terminal part with kinase domains separated by an interkinase stretch (22) . Binding of PDGFs to the extracellular domain of the receptor induces a conformational change to relieve an autoinhibitory constraint at the juxtamembrane domain on the intrinsic tyrosine kinase activity of the receptor (4, 6) . Dimeric receptors then undergo transphosphorylation at multiple tyrosine residues, which act as docking sites for many signaling proteins. Two important enzymes, c-Src and phosphatidylinositol (PI) 3 kinase bind, through their SH-2 domains to specific phosphotyrosine residues and act in tandem to increase proliferation of mesangial cells (11) . Another signaling protein Grb2 binds to the interkinase domain at phosphotyrosine-716 to activate the Ras/MEK/ Erk1/2 MAPK signaling, which also contributes to mesangial cell proliferation (10) .
MAPKs exist as a conserved family in a three-tiered hierarchical module. In this cascade, the proximal kinases respond to distinct extracellular stimuli to propagate signal to the terminal kinases, which undergo dual phosphorylation at the Thr-X-Tyr motifs present in the activation loop (43) . There are four family members of these kinases, Erk1/2, JNK, p38, and the most recent addition, Erk5 (30, 31) . Erk5 was originally identified as BMK (big MAPK)-1. The NH 2 terminus of Erk5 is required for its cytoplasmic targeting. The following kinase domain shares 66% sequence identity with that of Erk2 (44) . Furthermore, Erk5 contains a long COOH-terminal domain, which gives it twice the size compared with other MAPKs (46) . Although it was originally identified as a stress-activated MAPK, many growth factors and cytokines such as EGF, VEGF, FGF-2, PDGF, IL-6, and trophic factors like NGF and BDNF are known to activate this kinase (31) . Erk5 is abundantly expressed in many tissues including the heart (46) . Similarly abundant expression of Erk5 has been reported in renal glomeruli including glomerular mesangial cells (38) . Since PDGF plays an important role in inducing proliferation of mesangial cells in glomerular injury, we investigated the role of Erk5 in PDGF-induced proliferative response. Our results show that PDGF-stimulated Erk5 activation is necessary for proliferation of mesangial cells. We also demonstrate that Erk5 regulates cyclin D1-dependent inactivation of pRb to drive mesangial cell proliferation. We show that phosphatidylinositol 3-kinase (PI3-kinase) and its downstream target Akt kinase regulate PDGF-induced Erk5 phosphorylation. Furthermore, we provide evidence that a positive feedback loop involving Akt and Erk5 contributes to PDGF-induced mesangial cell proliferation.
MATERIALS AND METHODS
Materials. Recombinant PDGF BB (described as PDGF in RE-SULTS) was purchased from R&D Systems. Tissue culture materials and first-strand cDNA synthesis kit were obtained from Invitrogen. The PI3-kinase inhibitor Ly294002 and Akt inhibitor MK2206 were purchased from Calbiochem and Selleck Chemicals, respectively. The following antibodies were used: phospho-Erk5 (Thr-218/Tyr-220), anti-phosphotyrosine, phospho-Erk1/2 (Thr-202/Tyr-204), phosphopRb (Ser-795), phospho-Akt (Ser-473), phospho-Akt (Thr-308), phospho-GSK3␤ (Ser-9), Akt, GSK3␤, and Erk5 (Cell Signaling Technologies); phospho-PDGFR␤ (Tyr-857) and PDGFR␤ (Upstate Biotechnology); anti-actin and anti-FLAG (Sigma); pRb (Santa Cruz Biotechnology); and anti-HA (Covance). TRI reagent, phenylmethylsulfonylfluoride, Na 3VO4, and Nonidet P-40 were obtained from Sigma. XMD8-92 was purchased from Tocris Bioscience. FuGENE HD was purchased from Promega Dominant negative FLAG-Erk5, and constitutively active HA-MEK5 DD was kindly provided by Dr. Cathy Tournier (University of Manchester, Manchester, UK) and Dr. Melanie H. Cobb (University of Texas Southwestern Medical Center at Dallas), respectively (17, 32) . Expression plasmids for HA-cyclin D1, HA-CDK4, HA-PTEN, HA-Akt K179M (dominant negative Akt), and HA-Myr-Akt (constitutively active Akt) have been described previously (3, 7) . Two independent siRNAs targeted against Erk5 (siErk5A and siErk5B) were purchased from Sigma.
Cell culture. Rat glomerular mesangial cells were grown in DMEM in the presence of 17% fetal bovine serum as described previously (7, 14) . Cells were serum starved for 24 h to make them quiescent before incubation with 20 ng/ml PDGF for the indicated periods of time. In some experiments, the cells were treated with different inhibitors for 1 h before incubation with PDGF.
DNA synthesis and proliferation assays. DNA synthesis was determined using [ 3 H]thymidine incorporation assay as described previously (3, 7) . For measurement of cell proliferation, PDGF-treated mesangial cells were trypsinized at the indicated time periods and counted using a hemocytometer as previously described (3, 16) .
Cell lysis and immunoblotting. After treatment, the cell monolayer was washed with PBS. The cells were then lysed with radioimmunoprecipitation assay buffer (20 mM Tris·HCl pH 7.5, 5 mM EDTA, 150 mM NaCl, 1 mM Na 3VO4, 1 mM PMSF, 0.1% protease inhibitor cocktail, and 1% Nonidet-P40) at 4°C for 30 min. The crude extract was centrifuged at 12,000 g at 4°C for 30 min, the supernatant was collected, and protein was estimated. Equal amounts of proteins were separated by SDS-PAGE. The separated proteins were transferred to the PVDF membrane. Immunoblotting was performed using indicated antibodies. The protein signals were developed by horseradish peroxidase-conjugated secondary antibody using the ECL reagent as previously described (14, 15) .
RNA isolation and quantitative real-time RT-PCR. Total RNA was prepared from mesangial cells using the TRI reagent according to manufacturer's protocol. Expression of cyclin D1 was determined by quantitative real-time RT-PCR. One microgram of total RNA was used to make cDNAs using oligo-dT and MMLV reverse transcriptase reagents from Invitrogen. The cDNA was amplified and quantified in a 96-well plate using cyclin D1 primers (forward: 5=-CATCCG-CAAACATGCACAGACCTT-3= and reverse: 5=-TTTCTCTTCG-CGGATGCCACTACT-3=) in 7500 real-time PCR machine (Applied Biosystems) using PCR conditions of 94°C for 10 min followed by 45 cycles at 94°C for 30 s, 58°C for 30 s and 72°C for 30s. The level of mRNA was normalized by GAPDH in the same sample. Data were analyzed by comparative C t method as described previously (14) .
Transfection. Mesangial cells were transfected with plasmid vectors or siRNAs targeted against Erk5 using FuGENE HD essentially as described previously (14, 15) . For siRNA transfection, scrambled RNA was used as control.
Statistics. The significance of the data was analyzed by ANOVA followed by Student-Newman-Keuls analysis (11, 14, 15) .
RESULTS

Erk5 regulates PDGF-induced mesangial cell proliferation.
PDGF increases signal transduction pathways to initiate mitogenesis leading to proliferation of glomerular mesangial cells (1). Multiple kinases have been shown to contribute to PDGFinduced cell proliferation (10, 37) ; however, the role of Erk5 in this process has not been investigated. We examined the effect Erk1/2 ( Fig. 1, E and 1F ). These results indicate that XMD8-92 specifically blocks Erk5 without affecting Erk1/2 and PDGFR tyrosine kinase activity. To determine the role of Erk5 in mesangial cell proliferation, the effect of XMD8-92 on DNA synthesis and cell proliferation was measured. As expected, PDGF increased DNA synthesis that was significantly inhibited by XMD8-92 (Fig. 1G) . Similarly, XMD8-92 significantly attenuated PDGF-induced proliferation assessed by cell counting (Fig. 1H) .
To further examine the specificity of Erk5 in mesangial cell proliferation, we employed a vector expressing dominant negative Erk5. The results showed that expression of dominant negative Erk5 significantly inhibited PDGF-induced DNA synthesis (Fig. 1I) . Similarly, dominant negative Erk5 markedly blocked PDGF-induced mesangial cell proliferation assessed by cell counts (Fig. 1J ). These observations were validated using siRNAs targeted against Erk5 (siErk5A and siErk5B). Expression of siErk5A significantly prevented DNA synthesis and proliferation of mesangial cells in response to PDGF (Figs. 1, K and M). A second siRNA targeting Erk5 (siErk5B) produced similar results (Fig. 1, L and N) . Collectively, these data demonstrate that PDGF activates Erk5, which is required for proliferation of mesangial cells.
Erk5 controls cell cycle regulatory proteins. We have previously shown that PDGF regulates cell cycle proteins to promote mesangial cell proliferation (7, 11) . Cyclin D1 promotes S-phase entry to initiate DNA synthesis. Therefore, we determined the role of Erk5 in cyclin D1 expression. Incubation of mesangial cells with PDGF increased the expression of cyclin D1 mRNA (Fig. 2) . Inhibition of Erk5 using XDM8-92 blocked PDGF-induced cyclin D1 mRNA expression ( Fig. 2A) . Expression of dominant negative Erk5 also inhibited PDGFstimulated expression of cyclin D1 mRNA (Fig. 2B) . To confirm this observation, we used siRNAs targeted against Erk5. The Expression of two different siRNAs (siErk5A and siErk5B) abrogated cyclin D1 mRNA expression in response to PDGF (Fig. 2, C and D) . In similar experiments, we examined cyclin D1 protein expression. PDGF increased cyclin D1 protein levels in mesangial cells (Fig. 2, E-H) . Inhibition of Erk5 by XDM8-92 or dominant negative mutant abolished PDGF-stimulated cyclin D1 protein levels (Fig. 2, E and F) . Similarly, the two independent siRNAs targeting Erk5 inhibited PDGF-induced expression of cyclin D1 protein (Fig. 2, G  and H) .
Cyclin D1 regulates activation of CDK4/6, the G 1 cyclindependent kinases. These kinases phosphorylate the tumor suppressor pRb at Ser-795, resulting in its inactivation leading to cell cycle regulation. Thus we were interested in the involvement of Erk5 in this event. PDGF increased phosphorylation of pRb at Ser-795 (Fig. 3) . Inhibition of Erk5 by XDM8-92 or kinase dead mutant significantly attenuated the PDGF-induced phosphorylation of pRb (Fig. 3, A and B) . Also, expression of siErk5A and siErk5B targeting Erk5 significantly inhibited pRb phosphorylation by PDGF (Fig. 3, C and D) . These results together demonstrate a role for Erk5 in regulating cyclin D1/CDK4/6/pRb in mesangial cells.
Cyclin D1/CDK4 downstream of Erk5 regulates proliferation of mesangial cells. G 1 cyclins and their assisted kinases regulate S-phase entry of cells. We have shown that Erk5 regulates proliferation of mesangial cells (Fig. 1) . Because cyclin D1 is regulated by Erk5, we first examined the contribution of this cyclin in Erk5-mediated DNA synthesis. As expected, expression of dominant negative Erk5 inhibited PDGF-induced DNA synthesis (Fig. 4A) . However, expression of cyclin D1 increased the DNA synthesis and significantly prevented the dominant negative Erk5-mediated inhibition of PDGF-stimulated DNA synthesis (Fig. 4A) . Similarly, cyclin D1 enhanced proliferation and abrogated the inhibitory effect of dominant negative Erk5 on proliferation of mesangial cells induced by PDGF (Fig. 4B) . Expression of cyclin D1 produced identical effects on two different siErk5-induced suppression of PDGF-induced DNA synthesis and cell proliferation (Fig.  4, C-F) .
One of the downstream targets of cyclin D1 is CDK4. Phosphorylation of pRb by CDK4 results in its inactivation and induces S-phase entry. We have shown above that Erk5 regu- lates phosphorylation of pRb (Fig. 3 ). Therefore, we tested the involvement of CDK4 in Erk5-mediated mesangial cell proliferation. Expression of wild-type CDK4 increased DNA synthesis and proliferation and significantly reversed the dominant negative Erk5-mediated inhibition of PDGF-stimulated DNA synthesis and cell proliferation (Fig. 5, A and B) . Similarly, CDK4 restored the suppression of PDGF-mediated DNA synthesis and mesangial cell proliferation induced by expression of siErk5A and siErk5B targeting Erk5 (Fig. 5, C-F) . Collectively, these results demonstrate a role for Erk5 in regulating cyclin D1-dependent CDK4-mediated mesangial cell proliferation in response to PDGF.
PI3-kinase regulates PDGF-induced Erk5 phosphorylation.
We have previously shown that PI3-kinase regulates mesangial cell proliferation (8, 10) . Also, we reported that PI3-kinase controls cell cycle regulatory proteins in response to PDGF in mesangial cells (11). Since our above results demonstrate that Erk5 contributes to these processes, we tested the hypothesis that PI3-kinase is involved in Erk5 phosphorylation. We used the PI3-kinase inhibitor Ly294002. Incubation of mesangial cells with Ly294002 significantly inhibited PDGF-induced phosphorylation of Erk5 concomitant with attenuation of phosphorylation of Akt, a measure of PI3-kinase inhibition (Fig. 6,  A and B) (7) . Because Ly294002 is a nonspecific inhibitor of PI3-kinase activity, we used a deletion mutant of the p85 regulatory subunit of PI3-kinase (⌬p85) that renders dominant negative effect on this kinase (20) . The expression of dominant negative PI3-kinase markedly blocked phosphorylation of Erk5 (data not shown). To confirm this observation, we used, PTEN, which acts as an endogenous inhibitor of PI3-kinase signaling (28) . Similar to dominant negative PI3-kinase, expression of PTEN prevented Erk5 and Akt phosphorylation induced by PDGF (Fig. 6, C and D) . Erk5 regulates PDGF-induced Akt activation. We have shown previously that the PI3-kinase target Akt regulates PDGF-induced proliferation of mesangial cells (7, 11) . Because Erk5 also contributes to PDGF-stimulated proliferation of these cells (Fig. 1) , we tested whether Erk5 regulates Akt activation. The results showed that the Erk5 inhibitor XMD8-92 attenuated PDGF-induced Akt phosphorylation at Thr-308 and Ser-473 (Fig. 7A) . Because phosphorylation at both these sites of Akt increases its activity, we examined the phosphorylation of one of its endogenous substrates GSK3␤. XMD8-92 abrogated PDGF-stimulated phosphorylation of GSK3␤ (Fig. 7B) . Similarly, expression of dominant negative mutant of Erk5 significantly inhibited phosphorylation of Akt and GSK3␤ (Fig. 7, C and D) , which was verified by siRNAs targeting Erk5 (Fig. 7, E 
-H).
Erk5 is activated by its upstream kinase, MEK5. Thus we examined the role of MEK5 in activation of Akt using a constitutively active mutant of MEK5. As expected, expression of constitutively active MEK5 increased phosphorylation of Erk5 similar to that observed with PDGF (Fig. 7I) . Similarly, MEK5 increased phosphorylation of Akt at Ser-473 and Thr-308, resulting in its activation as indicated by the phosphorylation of GSK3␤ (Fig. 7, J and K) . These results demonstrate that MEK5/Erk5 signaling acts upstream of Akt kinase in mesangial cells.
Akt kinase regulates Erk5 phosphorylation. Akt is a downstream target of PI3-kinase that regulates PDGF-induced mesangial cell proliferation (7). Because Erk5 also contributes to mesangial cell proliferation, we postulated that Akt regulates Erk5 activation. We showed that an Akt kinase inhibitor MK2206 significantly inhibited PDGF-induced phosphorylation of Erk5 (Fig. 8A) . MK2206 also inhibited phosphorylation of the endogenous Akt substrate GSK3␤ (Fig. 8B) , demonstrating successful inhibition of Akt kinase activity. To confirm these results, a dominant negative mutant of Akt (Akt K179M) was transfected into mesangial cells. Expression of this Akt mutant blocked phosphorylation of Erk5 and GSK3␤ in response to PDGF (Fig. 8, C and D) . To further confirm these data, a constitutively active mutant, Myr-Akt, was used. Expression of Myr-Akt increased phosphorylation and activation of Akt as judged by phosphorylation of GSK3␤, similar to PDGF treatment of mesangial cells (Fig. 8, E and F) . Myr-Akt mimicked the effect of PDGF on Erk5 phosphorylation (Fig.  8G) . Collectively, these results conclusively show the presence of a positive feedback loop between Erk5 and Akt that drives PDGF-induced mesangial cell proliferation.
DISCUSSION
In the present study, we show activation of Erk5 in glomerular mesangial cells by PDGF, the mitogenic factor for these cells. We demonstrate that Erk5 is essential for PDGF-induced mesangial cell proliferation. Furthermore, Erk5 utilizes the classical cyclin D1/CDK4 pathway to increase pRb phosphorylation and mesangial cell proliferation. Interestingly, we report that PI3-kinase/Akt signal transduction regulates Erk5 phosphorylation by PDGF. Finally, we provide the first evidence for the presence of a positive feedback loop between Erk5 and Akt in PDGFR signaling (Fig. 9) .
Proliferation of mesangial cells is a major pathologic feature in proliferative and inflammatory glomerular diseases in human and in experimental animals (1, 24, 25) . Neutralization of PDGFR␤ prevents mesangioproliferative glomerulonephritis in rat (25) . These studies establish the importance of PDGFR signal transduction in proliferation of mesangial cells under pathological conditions (1) . PDGF induces pleotrophic effects including activation of phospholipase C, phospholipase A2, Erk1/2, PI3-kinase, and c-Src in mesangial cell (10, 11, 22) . Interestingly, it was previously shown that in vivo inhibition of Erk1/2 partially blocked increase in glomerular cell number observed in anti-thy-1-induced glomerulonephritis in rat (5) . It should be noted that in this study the activation of Erk1/2 was investigated as early changes during the course of disease progression. A more recent study using a rat model of combined uninephrectomy and anti-thy-1-induced mesangioproliferative glomerulonephritis demonstrated increased levels of phosphorylation of Erk5 in a prolonged fashion that coincided with enhanced extracellular matrix protein expression (38) . In this study, the in vitro viability of mesangial cells and collagen expression was shown to be dependent on Erk5. However, in the anti-Thy-1-induced proliferative glomerulonephritis, a significant role of PDGF has been established (1, 24, 25) . We have previously reported that in mesangial cells PDGF activates Erk1/2 MAPK downstream of PI3-kinase (10) . Furthermore, we showed that Erk1/2 partially contributes to the proliferation of mesangial cells induced by PDGF (7) (Fig. 9) . This observation supports the findings that Erk1/2 inhibition in anti-thy-1-induced glomerulonephritis only partially ameliorates increase in glomerular cell number (5) . Importantly, we established a significant contribution of PI3-kinase/Akt signaling in PDGF-stimulated mesangial cell proliferation (7, 10) . In the present study, we for the first time demonstrate that PDGF, which contributes to the pathogenesis of mesangioproliferative glomerulonephritis, increases phosphorylation of Erk5 in mes- angial cells (Fig. 1) . Importantly, our data show that Erk5 contributes to the proliferation of mesangial cells in response to PDGF (Fig. 1 ). An increased level of cyclin D1 is often associated with enhanced cell proliferation. Overexpression of cyclin D1 in mice increases cell proliferation (27, 41) . Also, PDGF significantly increases the expression of cyclin D1 in mesangial cells and is necessary for their proliferation (26) . Previously, it was shown that PI3-kinase regulates cyclin D1 expression in response to PDGF in smooth muscle cells (29) . However, Erk1/2 but not Erk5 was responsible for cyclin D1 expression in fibrosis (36) . In contrast to these studies, our results demonstrate contribution of Erk5 to PDGF-induced cyclin D1 in mesangial cell proliferation (Fig. 2) .
Cyclin D1 and CDK4 act cooperatively to drive cell cycle entry. Cyclin D1/CDK4 complex phosphorylates pRb, resulting in its inactivation. Microinjection of cells with cyclin D1/CDK4 complex phosphorylates pRb to induce cell cycle entry (12) . Furthermore, introduction of in vitro phosphorylated pRb by cyclin D1/CDK4 complex into cells increases DNA synthesis (13) . We found that in mesangial cells PDGFstimulated cyclin D1 increased the phosphorylation of pRb at the CDK4 site Ser-795. Interestingly, this phosphorylation is prevented by inhibition of Erk5 (Fig. 3) . In fact, expression of cyclin D1 or CDK4 reverses the reduction in PDGF-stimulated DNA synthesis and cell proliferation that results from Erk5 inhibition (Figs. 4 and 5) . Collectively, these results demonstrate a significant role of Erk5 in PDGF-induced cell cycle progression and proliferation of mesangial cells. The role of class IA PI3-kinase in proliferation and survival of cells is established. We have previously shown that PDGFstimulated PI3-kinase activity is essential for proliferation in mesangial cells and metanephric mesenchymal cells, a subpopulation of which differentiate into mesangial cells (2, 10, 11,  34 ). In the present study, we identified Erk5 as an effector of PI3-kinase signaling that contributes to proliferation of mesangial cells using a pharmacological inhibitor, dominant negative PI3-kinase, and an endogenous inhibitor of PI3-kinase, PTEN (Fig. 6 and data not shown) . One of the downstream targets of PI3-kinase is Akt. This kinase is activated by variety of extracellular stimuli including PDGF (18) . We showed previously that PDGF activates Akt in mesangial cells, resulting in regulation of cell cycle proteins (7, 11) .
Recently, a role of Erk5 in activation of Akt kinase was reported by osmotic stress, NGF and VEGF in regulating cell survival (17, 23, 33, 35, 42) . More recently, Erk5 was shown to increase Akt phosphorylation in dermal microvascular endothelial cells in response to VEGF. However, this activation increased tubular morphogenesis without having an effect on proliferation of these cells (35) . In the present study, we find that both Erk5 and its upstream kinase MEK5 regulate phosphorylation of Akt at both Thr-308 and Ser-473 in mesangial cells, resulting in their proliferation (Figs. 1 and 7) . Surprisingly, we found that inhibition of Akt significantly blocked phosphorylation of Erk5 in response to PDGF (Fig. 8) . To our knowledge, this is the first demonstration for the presence of a positive feedback loop between Akt and Erk5 in the PDGFR signaling (Fig. 9) . These results corroborate our previous studies demonstrating a role of Akt kinase in mesangial cell proliferation (7, 11) . Further studies will be necessary to delineate the mechanism of this feedback loop. Many Akt kinase inhibitors have been developed; however, they display severe toxicity. As our results demonstrate Erk5 as a potent mediator in the signaling circuit of PDGF leading to mesangial cell proliferation, development of safe inhibitors targeting this kinase will be beneficial for mesangioproliferative glomerulonephritis. 
